REFERENCES
- http://www.eiu.com/siteinfo.asp?info name = LAF&page = noads (Accessed 2012 July 9).
- Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265–277.
- Anguille S, Lion E, Smits E, Berneman ZN, van Tendeloo VF. Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers. Hum Vaccin 2011; 7: 579–584.
- Anguille S, Van Tendeloo VF, Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012.
- Anguille S, Willemen Y, Lion E, Smits EL, Berneman ZN. Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy 2012; 14: 647–656.
- Van de Velde AL, Berneman ZN, Van Tendeloo VF. Immunotherapy of hemato-logical malignancies using dendritic cells. Bull Cancer. 2008 Mar; 95(3): 320–326.
- Van Tendeloo VF, Van de Velde A, de Vries IJ, Sugiyama H, Berneman ZN. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A. 2010 Aug 3; 107(31): 13824–13829.
- Anguille S, Van Tendeloo V, Berneman Z. Dendritic cell-based therapeutic vac-cination for acute myeloid leukemia. Bull Cancer 2012; 99: 635–642.
- Finn OJ. Cancer immunology. N Engl J Med 2008; 358: 2704–2715.
- Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006; 17:563–570.
- Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castra-tion-resistant prostate cancer. N Engl J Med 2010; 363:411–422.
- Karan D, Holzbeierlein JM, Van Veldhuizen P, Thrasher JB. Cancer immunother-apy: a paradigm shift for prostate cancer treatment. Nat Rev Urol 2012.
- Berneman ZN. Autologous T cells on the attack against AML. Blood. 2012; 120(6): 1151–1152.
- Anguille S, Smits EL, Cools N, Goossens H, Berneman ZN, Van Tendeloo VF. Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med 2009; 7: 109.
- Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current para-digms. Clin Cancer Res 2007; 13: 3776–3782.